X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Melt Pharmaceuticals will utilize Catalent’s proprietary Zydis® orally disintegrating tablet fast-dissolve technology with MELT-300 (midazolam), a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Melt-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melt Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 26, 2023
Details:
Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 03, 2023
Details:
Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rivive
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harm Reduction Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2023
Details:
The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmaceutics™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2023
Details:
PSI-GAD (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Incannex Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Under the terms of the license agreement, Catalent and Ethicann will develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology including EPI-002 (cannabinoid) candidate to treat MS spasticity.
Lead Product(s): Cannabinoid
Therapeutic Area: Musculoskeletal Product Name: EPI-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ethicann Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 12, 2023
Details:
INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acorda Therapeutics
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of essential components of dystrophin.
Lead Product(s): Delandistrogene Moxeparvovec
Therapeutic Area: Genetic Disease Product Name: SRP-9001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: $30.0 million
Deal Type: Licensing Agreement November 03, 2022
Details:
The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for 3,4-methylenedioxy-methamphetamine (MDMA) using Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Awakn Life Sciences Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
